Signal Pharmaceuticals, Ares-Serono deal

The companies expanded their 1997 collaboration to identify small molecule modulators of NF-kB gene regulation to treat autoimmune and inflammatory diseases (see BioCentury, Dec. 8, 1997). As expande...